What is Exo Therapeutics?
Exo Therapeutics, based in Boston, MA, is a biopharmaceutical company dedicated to the discovery and development of small molecule drugs. The company's focus on innovative therapeutic approaches positions it within the competitive landscape of drug development, aiming to address unmet medical needs through advanced scientific research and strategic partnerships.
How much funding has Exo Therapeutics raised?
Exo Therapeutics has raised a total of $103M across 2 funding rounds:
Series A
$25M
Series B
$78M
Series A (2020): $25M with participation from Novartis Venture Fund, CRV BV, Newpath Partners, and Dimensions Capital
Series B (2021): $78M led by BVF Partners, Nextech Invest, Morningside, L.P., and Samsara BioCapital
Key Investors in Exo Therapeutics
Nextech Invest
Nextech Invest is a Zurich-based company dedicated to accelerating advancements in precision medicine by identifying transformative cancer medicines. They focus on nurturing emerging biotechnology companies worldwide, particularly during critical moments of scientific validation and value creation.
Samsara BioCapital
Samsara BioCapital is focused on investing to create transformative therapeutics for patients. The company partners with scientists, physicians, drug developers, and business leaders to support the next generation of therapeutic breakthroughs.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide.
What's next for Exo Therapeutics?
The recent major enterprise-level funding, characterized as a strategic investment, indicates that Exo Therapeutics is likely in a scaling phase, potentially preparing for late-stage clinical trials or market expansion. This capital infusion will be crucial for advancing its pipeline of small molecule drug candidates and solidifying its market position. The company's trajectory suggests a continued focus on innovation and strategic collaborations to bring novel therapeutics to patients.
See full Exo Therapeutics company page
